MDM2 and liposarcoma: Notably, Tabareau-Delalande et al. identified MDM2 amplification by qPCR in 26% (12/47) of craniofacial BFOLs, and interestingly, 75% (9) of the amplified cases were juvenile ossifying fibromas; however, MDM2 expression was not observed in any of the 47 craniofacial BFOLs even though all the controls (15 well-differentiated/dedifferentiated liposarcomas) showed expression of MDM2 [35].